Navigation Links
Inscent, Inc. Receives Federal Grant to Develop Honeybee Repellents
Date:4/28/2008

IRVINE, Calif., April 28 /PRNewswire/ -- Inscent, Inc. has received a Small Business Innovative Research grant from the US National Science Foundation (NSF) to continue the testing and development of novel honeybee repellents using the proprietary Attenu high throughput assay system. The pioneering research performed by Inscent, Inc. has resulted in highly efficient processes that allow the rapid development of revolutionary insect control products suited for the modern age. Inscent's groundbreaking paradigm shift away from traditional insecticides and toward products based on behavior alteration of targeted species has been supported extensively by federal research grants and private industry funds. NSF reviewers described the honeybee repellent project as "fascinating" and "highly desirable," and new federal funding commences in July 2008.

Inscent, Inc. is designing environmentally responsible insect control products that will eclipse the current generation of insecticides. The company's latest efforts focus on the honeybee, Apis mellifera, an economically and agriculturally crucial insect species, for the development of a new array of insect control products based on behavior alteration. Inscent's honeybee repellent project was originally funded by the Citrus Research Board (CRB; http://www.citrusresearch.org), a coalition of California growers at the global forefront of citrus industry-funded scientific research.

The honeybee, Apis mellifera, is critical to US agriculture, and a Cornell University study estimated the direct value of honeybee pollination in this country exceeds $14 billion annually. Although the initial use of the repellent will be to prevent seediness in mandarins, it will also provide a solution for keeping bees out of fields that have been treated with insecticides. Honeybees are threatened by insecticide use and recent incidents of colony collapse have caused great concern among the farming and apiculture industries. These factors have combined to generate an urgent need for effective products that are safe to humans and insects alike.

Inscent, Inc. has developed a number of novel platform technologies to exploit the wide variety, selectivity, and high sensitivity of insect chemosensory systems. This proprietary collection of chemosensory proteins is being used to develop a series of non-toxic, highly efficient insect pest control products. Inscent's new technologies are applicable to a wide array of insect pest species that impact the agricultural, domestic, and public health sectors. Inscent's platform technologies utilize the latest developments in molecular genetics, genomics, and bioinformatics to design advanced, environmentally responsible insect pest control solutions and effective, sensitive biosensors. Further information on Inscent is available on the web at http://www.inscent.com.

The National Science Foundation is an independent federal agency that supports fundamental research and education across all fields of science and engineering. NSF also encourages scientific innovation and discovery in the commercial sector, primarily through the Small Business Innovative Research (SBIR) program. Further information on NSF is available on the web at http://www.nsf.gov.

Inscent, Inc. welcomes inquiries from qualified investors and potential strategic allies.


'/>"/>
SOURCE Inscent, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... On Dec. ... the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight individuals who have ... (MPNs) by going above and beyond the standard of care, demonstrating leadership within the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... the launch of its 60-day free trial program for all of the company’s ... the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of ... of an injury, patients must find the one that works for them. When an ... created a machine that worked and decided to share it with others. , He ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet is proud to announce the ... the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and ... 6 years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the ... its unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition ... has been available in several ShopRite and FoodTown stores in NJ and received rave ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016  The Addiction Treatment ... Academy of Managed Care Pharmacy (AMCP), has released ... better address the opioid addiction crisis, including through ... (MAT). ATAG,s newly released paper, "The ... to Naloxone," addresses many issues around gaps and ...
(Date:12/2/2016)... R.I. , Dec. 2, 2016 CVS ... its annual Analyst Day in New York City on Thursday, December 15, ... CVS Health leadership team will provide an in-depth review ... enhance shareholder value. The company will also discuss 2017 ... and video webcast of the event will be broadcast ...
(Date:12/2/2016)... Dec. 2, 2016   CytoSorbents Corporation (NASDAQ: ... its European Union approved CytoSorb ® cytokine adsorber ... patients worldwide, announced that Dr. Phillip Chan , ... Annual LD Micro Main Event investor conference held ... the Luxe Sunset Boulevard Hotel in Los ...
Breaking Medicine Technology: